2018 ASCO: Neoadjuvant Use of PARP Inhibitor Shows Promise in Early-Stage, BRCA-Mutated Breast Cancer - The ASCO Post

2018 ASCO: Neoadjuvant Use of PARP Inhibitor Shows Promise in Early-Stage, <em>BRCA</em>-Mutated Breast Cancer - The ASCO Post

2018 ASCO: Neoadjuvant Use of PARP Inhibitor Shows Promise in Early-Stage, BRCA-Mutated Breast Cancer

By The ASCO Post
Posted: 6/5/2018 10:21:18 AM
Last Updated: 6/5/2018 10:21:18 AM

Key Points

• At the time of surgery, the researchers found that 53% of the women (10 of 19) achieved pathologic complete response, or a score of RCB0; combined, 63% (12 of 19) received a score of RCB0 and RCB1.
• Toxicities included blood count deficiencies, which could be managed by close monitoring of cell counts and platelets and by giving dose reductions and transfusions. Some patients also experienced grade 1 alopecia.